Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Depreciation and Depletion (2023 - 2025)

Standard Biotools (LAB) has disclosed Depreciation and Depletion for 3 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion rose 50.0% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.6 million, a 78.38% increase, with the full-year FY2023 number at $3.4 million, up 21.43% from a year prior.
  • Depreciation and Depletion was $1.5 million for Q3 2025 at Standard Biotools, up from $800000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $3.3 million in Q1 2025 to a low of -$1.0 million in Q2 2024.
  • A 3-year average of $1.3 million and a median of $1.0 million in 2024 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: surged 328.57% in 2024, then increased 10.0% in 2025.
  • Standard Biotools' Depreciation and Depletion stood at $700000.0 in 2023, then skyrocketed by 42.86% to $1.0 million in 2024, then skyrocketed by 50.0% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Depreciation and Depletion are $1.5 million (Q3 2025), $800000.0 (Q2 2025), and $3.3 million (Q1 2025).